Journey Medical reports FY2021 record revenue of $63.1M, net loss of $44.0M; DFD-29 Phase 3 underway

Journey Medical Corp

Record net product revenues of $63.1M in FY2021, up 42% from $44.5M in FY2020.
Net loss attributable to common stockholders of $44.0M ($4.32/share) vs net income of $5.3M ($0.58/share) in FY2020.
Non-GAAP adjusted EBITDA positive at $2.9M; non-GAAP net loss of $16.9M ($1.66/share).
Cash and equivalents $49.1M at Dec 31, 2021, up from $8.2M a year ago, boosted by IPO proceeds.
Dosed first patient in Phase 3 for DFD-29 for rosacea; received $10M milestone from Maruho; acquired VYNE MST franchise for $20M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.